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Poster Session-II 1550.8 mg/kg often failed to achieve our target AUC of 1150–1350. Fif-
teen AML/MDS patients receiving 0.8 mg/kg had a mean AUC of
1059 (822–1653), with 12 AUCs\1150. Subsequently, our routine
starting dose of IV Bu was changed to 0.9 mg/kg.
Methods: We performed a retrospective review of AML and
MDS patients from an IRB approved HIPAA compliant database es-
tablished for the collection and analysis of Bu PK. Data from two
groups of Bu patients treated between 1998 and 2008 were analyzed.
Fifty-eight patients were treated with oral Bu (1 mg/kg) and fifty-
eight patients were treated with IV Bu (0.9 mg/kg). Bu AUC was de-
termined for the first dose and adjustments were made on subsequent
doses to target an AUC of 1150–1350.
Results: Median age for IV and oral Bu patients was 42 (18–68)
and 47 (23–67), respectively (p 5 0.0049). The mean terminal half-
life (T1⁄2 ) was 186 minutes (131–253) for IV Bu and 181 minutes
(110–305) for oral Bu (p 5 NS). Mean AUCs were 1115 (777–
1569) for IV Bu patients and 1260 (654–2019) for oral Bu (p 5
0.0094). Seventeen (29.3%) patients in each group achieved AUCs
within our target of 1150–1350. Thirty-four (58.6%) IV Bu patients
had AUCs\1150 compared to twenty (34.5%) oral Bu patients (p5
0.0092). Eight (13.8%) IV Bu patients had AUCs .1350 compared
to twenty-one (36.2%) oral Bu patients (p 5 0.0053).
Conclusions: While first dose PK analysis showed similar T1⁄2 for
IV and oral Bu, the AUCs achieved with 0.9 mg/kg IV Bu are lower
than with 1mg/kg oral Bu dosing. First-dose AUC from recipients of
IV Bu had a lower variance than AUC from recipients of oral Bu.
Despite changing our starting IV Bu dosing from 0.8 mg/kg to
0.9 mg/kg, the majority of patients still require therapeutic drug
monitoring with dose adjustments to obtain our desired target
AUC of 1150–1350.442
ARETROSPECTIVE ANALYSIS OF RISK FACTORS THAT INFLUENCE INTRA-
VENOUS BUSULFAN KINETICS IN ADULT PATIENTS
McBride, A.1, Fancher, K.1, Perkins, J.1, Milone, M.2, Shaw, L.2,
Conwell, M.1 1H. Lee Moffitt Cancer Center & Research Institute,
Tampa, FL; 2Hospital of the University of Pennsylvania, Philadelphia, PA
Busulfan (Bu) is a bifunctional alkylating agent that is a common
component of conditioning regimens prior to hematopoetic stem
cell transplantation (HSCT). Bu pharmacokinetics, either with area
under the curve (AUC) or average concentration at steady state
(Css), can be utilized to evaluate efficacy and prevent adverse effects
such as hepatic veno-occlusive disease (VOD). Pharmacokinetic
models that predict Bu levels were historically performed with q 6
hour oral dosing in the pediatric population and used a limited linear
regression model. Since the advent of intravenous (IV) Bu, a consistent
pharmacokinetic modeling system based on specific patient parame-
ters has not emerged. Likewise, current Bu pharmacokinetics models
may not be accurate in adult patients or with once-daily dosing sch-
edules. We will report a retrospective study of approximately 300
patients and present a predictive pharmacokinetic model for appropri-
ate AUC with once-daily IV Bu in adult patients. Our model will be
based on first dose kinetic analyses. We will also evaluate currently
published risk factors that may influence IV Bu kinetic parameters us-
ing univariate, multivariate and stepwise Cox regression analyses. Age,
race, gender, disease state, disease status at time of transplantation,
number of previous chemotherapy regimens, renal and hepatic func-
tion at time of transplant and graft source will be evaluated. Long-
term outcomes to be examined include overall mortality, probability
of survival, development of acute and chronic graft versus host disease
(GVHD), development of VOD and days until neutrophil and platelet
engraftment. Statistical model design and specific data results will be
presented at the 2009 ASBMT Annual Conference.443
AN ANALYSIS OF TOXICITIES AND TIME TO ENGRAFTMENT ASSOCIATED
WITH THREE DISTINCT MELPHALAN TREATMENT SCHEMAS IN PA-
TIENTS WITH MULTIPLE MYELOMA RECEIVING AUTOLOGOUS HEMATO-
POETIC STEM CELL TRANSPLANTATION
Maewal, I.1, Kurtzweil, A.J.1, Shapiro, J.F.2, Westmoreland, M.D.1,
Bassett RL Jr., Jr.,3, Giralt, S.A.4 1MD Anderson Cancer Center, Hous-
ton, TX; 2H. Lee Moffitt Cancer Center and Research Institute, Tampa,FL; 3MDAnderson Cancer Center, Houston, TX; 4MDAnderson Cancer
Center, Houston, TX
At MD Anderson Cancer Center, the standard-of-care prepara-
tory regimen in patients with multiple myeloma receiving an autol-
ogous stem cell transplant is melphalan 200 mg/m2 given over two
days with one day of rest prior to transplant. The primary objective
of this study is to determine if differences exist in the severity of tox-
icities in patients with multiple myeloma who receive melphalan as
a preparatory regimen in three distinct treatment schema. The sec-
ondary objective of this study is to ascertain the differences in time
to engraftment in this population. Toxicities, defined as nausea,
vomiting, diarrhea, renal and hepatic dysfunction, were graded using
the NCI-CTCAE. Pain secondary to mucositis was recorded based
on the use of patient-controlled analgesia. We performed a retro-
spective review in patients who received one of the following prepa-
ratory regimens: arm 1) melphalan 200 mg/m2 over days -3 and -2,
arm 2) melphalan 200 mg/m2 over day -2, or arm 3) melphalan
200 mg/m2 over days -2 and -1. This review included patients over
the age of 18 in first remission or with primary refractory disease
who received autologous transplantation within 12 months of diag-
nosis. Patients who received prior transplantation were excluded
from this review. 164 patients were identified from the institutional
database for data collection and 100 patients were selected at random
for this interim analysis. The majority of patients identified were
male,\65, ISS stage of I-II, and had an ECOG performance status
of 0–1. With respect to the primary endpoint, no statistically signif-
icant differences were observed in the severity of toxicity when com-
paring the treatment schemas (nausea: p5 0.55; vomiting: p5 0.46;
diarrhea: 0.52, Kruskal-Wallis test and PCA use secondary to mu-
cositis: p 5 0.82, Fisher’s exact test). With regard to time to en-
graftment, the actual difference between the arms was
approximately 1 day, yet the comparison between the three groups
was statistically significant (p\0.001, log-rank test). We concluded
that differences between the three treatment schemas in the severity
of toxicities were neither statistically nor clinically significant; the
differences in time to engraftment were not clinically significant.
Based on the interim analysis, this review demonstrates the poten-
tial for melphalan to be administered in any one of three distinct
treatment schemas without resulting in adverse effects on toxicity
and time to engraftment.
Results
Arm 1 Arm 2 Arm 3Grade 3-4 Toxicity(N544) (N537) (N519)n (%) n (%) n (%)Nausea 2 (4.5%) 1 (2.7%) 0
Vomiting 2 (4.5%) 0 0
Diarrhea 0 2 (5.4%) 0
Serum creatinine 0 0 0
Total bilirubin 0 1 (2.7%) 0
Pain 5 (11.4%) 4 (10.8%) 1 (5.3%)
Time to engraftment (median) 10 days 11 days 10 days444
SUCESSFUL OUTCOME AFTER ACCIDENTAL HIGH DOSE CYTARABINE (HI-
DAC) INFUSION SEVEN DAYS POST UNRELATED DONOR (UD) CORD
BLOOD (CB) STEM CELL TRANSPLATION (SCT)
Stelts, S., Nath, R. Methodist University Hospital/University of Tennessee
Cancer Institute, Memphis, TN
Introduction:The complex regimens of allogenic SCT increase
the risk of medication errors. We report an accidental HIDAC infu-
sion post UD-CBSCT and the patient outcome.
Case Report: A 24 year old heavily pretreated female with history
of relapsed philadelphia (Ph) positive acute lymphoblastic leukemia
received a 4/6 matched UD-CBST. The patient received a prepara-
tory regimen of fludarabine 30 mg/m2 on days -7 to -3, melphalan
70 mg/m2 on day -3 and -2, and antithymocyte immunoglobulin
10mg/kg on days -4 and -2. Graft versus host disease (gvhd) prophy-
laxis consisted of tacrolimus (level 5 -15 ng/ml) and mycophenolate
156 Poster Session-IImofetil (MMF) starting day -1. On day 17, the patient received an
accidental dose of HIDAC 3700 mg/m2 (6000mg) over 3 hours
instead of MMF. Patient developed worsening of her nausea and
vomitting but was controlled with antiemetics. She engrafted her
neutrophils with her absolute neutrophil count (ANC) .500/ml on
day 133 and .1000/ml on day 135 post SCT. She engrafted her
platelets with her untransfused platelet count . 20,000/ml on day
143 and.50,000/ml on day154 post SCT. Patient did not develop
any acute gvhd. On day 136 the patient was discharged from the
hospital. Patient had CNS relapse on day 171 (positive CSF cytol-
ogy and leptomeningeal enhancement on an MRI) but no systemic
disease (bone marrow biopsy 99–100% donor chimerisim and nor-
mal cytogenetics). The patient’s treatment included intrathechal li-
posomal cytarabine 50 mg on day 172 and 196, HIDAC 3000
mg/m2 every 12 hours for 10 doses from day 177 to 182 and dasa-
tinib 140 mg orally daily from day178 to183. Tacrolimus was dis-
continued on day177. The patient was neutropenic for 37 days (day
184 to1120) but achieved a remission in her CNS. At day1175 pa-
tient is alive, disease free, without gvhd off all immunosuppression
with normal ANC with 100 percent donor chimerism.
Discussion: There is no literature on HIDAC infusion post allo-
geneic SCT. Published data suggests that the longer duration of cy-
tarabine exposure is more cytotoxic to hematopoietic cells than the
dose. Other chemotherapeutic agents including methotrexate and
cyclophosphamide has been given posttransplantation for gvhd pro-
phylaxis and graft enhancement. HIDAC infusion post CBSCT did
not significantly delay neutrophil or platelet engraftment as com-
pared to published literature but may have contributed to lack of
gvhd in this patient inspite of withdrawl of all immunosuppression
by day 177.445
CIDOFOVIR USE IN THE ERADICATION OF POLYOMAVIRUS IN HEMATO-
POIETIC STEM CELL TRANSPLANT RECIPIENTS
Kenealy, L.K.1, O’Neal, N.K.1, Williams, C.B.1, Wilhauk, J.2,
Hoffman, T.2, Aljitawi, O.S.2, Abyhankar, S.2, McGuirk, J.P.2,
Ganguly, S.2 1University of Kansas Hospital, Kansas City, KS; 2Univer-
sity of Kansas Hospital, Kansas City, KS
Hemorrhagic cystitis caused by polyomavirus virus (BKV) is
a common complication following high dose chemotherapy and he-
matopoietic stem cell transplant. Low dose cidofovir has been shown
to be useful in the eradication of BKV post transplantation without
significant side effects. Controversy exists over the effective dose, du-
ration, and administration technique for cidofovir. Recent data
shows utilization of a dose range of 0.25–1mg/kg IV weekly. The
purpose of this review is to establish an optimal dose, duration,
and monitoring standards for cidofovir use in a future prospective
trial. This information will be further utilized at our institution to
implement an evidence- based standard of practice. A retrospective
review was completed on 13 patients with symptomatic BKV who re-
ceived cidofovir during a 15-month period. Cidofovir dose was given
without probenecid and initiated at 0.5mg/kg intravenously weekly.
If no significant reduction in viral copies was seen, the dose was es-
calated to 1mg/kg. Patients were monitored for a molecular response
in both urine and plasma for BK viral load. Molecular response was
defined as a decrease in viral load by one log reduction with a consis-
tent decreasing trend. Patients received cidofovir for an average of
7.6 weeks. Urinary response was shown in 7/13 (54%) and plasma re-
sponse in 6/9 (67%) patients. Plasma PCR data was not measured in
5 patients. Transplant-related mortality occurred in 5 patients with80% (4/5) not responding in the urine to treatment. Acute renal fail-
ure, defined as an increase of 0.5mg/dL from baseline, occurred in 1/
13 (7.6%). Based on this data, we plan to enroll patients into a ran-
domized study using 0.5mg/kg or 1mg/kg weekly intravenous cido-
fovir to determine the most effective treatment regimen for
symptomatic patients while minimizing toxicity. Patients will have
BKV PCR analysis weekly on blood and urine to determine eradica-
tion and optimal length of therapy. Data will be examined to deter-
mine if therapy can be discontinued based on clinical response or
molecular response. Due to the renal dysfunction associated with
cidofovir, serum creatinine will also be monitored. Results from
this trial will be valuable since no current standard of care for BK
viremia exist.446
ADDITION OF URSODIOL IN ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANT TO REDUCE THE RISK OF VENOUS OCCLUSIVE DISEASE
AND GRAFT VERSES HOST DISEASE
Kenealy, L.K.1, Brinkman, J.L.1, McFarland, K.L.1, Williams, C.B.1,
Hoffman, T.2, Wilhauk, J.2, Aljitawi, O.S.2, Ganguly, S.2,
McGuirk, J.P.2, Abhyankar, S.2 1University of Kansas Hospital, Kansas
City, KS; 2University of Kansas Hospital, Kansas City, KS
Venous-occlusive disease (VOD) and graft-versus-host disease
(GVHD) are devastating complications of allogeneic hematopoietic
stem cell transplants (HSCT). Mortality has been estimated to be as
high as 30% for VOD and 40% for GVHD, which remains the main
cause of morbidity associated with HSCT. The use of prophylactic
ursodiol is believed to provide protection against complications.
However, clinical evidence for the use of this medication is limited
and the duration of therapy has not been established in non-myeloa-
blative pre-transplant regimens. The primary objective of this retro-
spective review is to determine the incidence and severity of VOD
and GVHD in allogeneic HSCT patients not receiving prophylactic
ursodiol. Thirty-four patients that underwent allogeneic HSCT in
2007 who did not receive ursodiol prophylaxis were evaluated. Acute
GVHD was staged as level 0–4 based on quantification of skin rash,
serum bilirubin, and gastrointestinal tract involvement. Chronic
GVHD will be graded as level I-IV based on the degree of skin
and organ involvement and clinical performance status. VOD will
be graded based on the Baltimore criteria which include jaundice
(bilirubin$ 2.0 mg/dL) and two of the following: hepatomegaly, as-
cites or$ 5% weight gain. Chronic GVHD and VOD data is yet to
be determined. Stage of acute GVHD in patients that were evaluated
is shown below in table 1.
Acute GVHD incidence in 34 patients
Grade 0 Grade 1 Grade 2 Grade 3 Grade 426% (n59) 29% (n510) 32% (n511) 8.8% (n53) 3% (n51)Acute GVHD was seen more often in non-myeloablative (average
grade 1.6, n 5 15) versus myeloablative protocols (average grade
1.2, n5 19). The second phase of this trial will evaluate the incidence
of VOD and GVHD in patients who receive prophylactic ursodiol.
This data will be compared to the patient population that did not
receive prophylaxis to determine the outcome. This data will be
helpful in determining the effectiveness of prophylactic ursodiol in
non-myeloablative HSCT.
